Status:
COMPLETED
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension.
Detailed Description
Despite the established benefits of beta-blockers, their use is limited by their side effect profile and by a perception of reduced efficacy in certain populations such as African Americans (Amudha, 2...
Eligibility Criteria
Inclusion
- African Americans with stage 1-2 hypertension
Exclusion
- Recent myocardial infarction or stroke
- Contraindications to beta-blocker therapy or stopping prior antihypertensive therapy
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT00145210
Start Date
April 1 2005
End Date
September 1 2007
Last Update
March 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505